During this 3 day CME course, experts in the field of cardiovascular genetics and genetic cardiology detail the important role of genetics, genomics, and pharmacogenetics in the diagnosis, risk stratification, and treatment of diseases affecting the heart and the blood vessels.
Topics covered will include, genetics and genomics 101, pharmacogenetics, polygenic risk scores, variant interpretation, the molecular autopsy, and the diagnostic, prognostic, and therapeutic implications of genetic testing for patients with congenital heart disease, long QT syndrome, Brugada syndrome, hypertrophic/dilated/arrhythmogenic cardiomyopathy, coronary heart disease, hyperlipidemias, heart failure, pulmonary hypertension, cardiac amyloid, and the aortopathies.
Unique Features: Audience response system to enhance immediate feedback. Easy access to faculty members. One-on-one interaction. Efforts will be made to introduce the clinical applications using new technology, however, there is no hands-on experience provided. Self-assessment questions to gauge outcome. A special workshop will be conducted to analyze your genetic test reports and to comment on the significance of the genetic test results and the implications for your patients.
On Thursday September 24, 2020 at 7:00 am (ends Saturday September 26, 2020 at 12:00 pm)
Venue Name: Sheraton Grand at Wild Horse Pass
Prior to Sept. 2 - Course Registration (MD, PhD, DO) : USD 650.0,
Prior to Sept. 2 - Course Registration (Medical Students, Fellows in Training, PA, NP, RN, GC, PharmD) : USD 500.0